FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021844653> ?p ?o ?g. }

• W2021844653 endingPage "298" @default.
• W2021844653 startingPage "291" @default.
• W2021844653 abstract "Objective: The primary aim of the study was to evaluate the effectiveness and tolerability of aripiprazole on motor and vocal tics in children and adolescents with Tourette's disorder (TD). The secondary aim was to assess the response of TD-associated behaviors to aripiprazole exposure. Methods: This was an 8-week, open-label trial with flexible dosing strategy of aripiprazole in children and adolescaents with TD. A total of 72 patients, aged 6–18 years, participated in the 8-week trial. The Yale Global Tic Severity Scale (YGTSS), the Clinical Global Impressions–Tics (CGI–Tics), and the Child Behavior Checklist (CBCL) were compared at the baseline, weeks 2 and 4, and end point. The side effects of aripiprazole, electrocardiogram (ECG), and body mass index (BMI) were evaluated. Results: Over the 8-week trial, aripiprazole administration was associated with a significant decrease in total tic severity as measured by the YGTSS (50.3% reduction by week 8). The mean scores of motor tic in the YGTSS were 17.42 ± 4.83, 12.93 ± 3.76, 8.39 ± 3.70, and 6.75 ± 3.95 at baseline, weeks 2 and 4, and end point. A significant decrease in the scores was observed in week 2 compared to the baseline, and the scores continued to decrease for the remainder of the study period (degrees of freedom [df ] = 3, F = 96.02, p = 0.000). The mean phonic tic scores were 12.71 ± 4.60, 8.53 ± 3.26, 6.10 ± 2.50, and 3.63 ± 2.20 at baseline, weeks 2 and 4, and end point, respectively. A significant change was observed during week 2 compared to the baseline, and this change continued for the rest of the study period (df = 3, F = 95.16, p = 0.000). Significant improvement was also observed according to the CGI–Tics severity. The mean CGI–Tics severity score was 4.77 ± 1.69 at baseline and decreased to 2.20 ± 1.39 at end point (t = 10.70, p = 0.000). A significant reduction of behavior symptoms was noticed according to the CBCL and its subscales between baseline and end point. The majority of subjects tolerated aripiprazole well. The extrapyramidal symptoms (EPS) during this study were negligible. In all 21 (29.2%) of the 72 participants complained of nausea and 19 (26.4%) of them reported sedation. There was no significant difference of BMI between the two phases (df = 64, t = −0.94, p = 0.352). There were no significant changes in laboratory results. ECG monitoring revealed no significant impact on cardiac conduction by aripiprazol. Conclusion: In this preminary open-label trial, aripiprazole showed effectiveness in treating tic symptoms without causing significant weight gain or other serious side effects. Aripiprazole could be an option for TD cases that do not respond to conventional therapies. Further controlled, double-blind studies are warranted." @default.
• W2021844653 created "2016-06-24" @default.
• W2021844653 creator A5027835055 @default.
• W2021844653 creator A5035282947 @default.
• W2021844653 creator A5052383569 @default.
• W2021844653 creator A5076359094 @default.
• W2021844653 creator A5078144552 @default.
• W2021844653 date "2010-08-01" @default.
• W2021844653 modified "2023-09-24" @default.
• W2021844653 title "Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette's Disorder: A Pilot Study in China" @default.
• W2021844653 cites W1963532188 @default.
• W2021844653 cites W1963575050 @default.
• W2021844653 cites W1970562208 @default.
• W2021844653 cites W1978577541 @default.
• W2021844653 cites W1985132002 @default.
• W2021844653 cites W1991610592 @default.
• W2021844653 cites W1998618539 @default.
• W2021844653 cites W2001900074 @default.
• W2021844653 cites W2007025029 @default.
• W2021844653 cites W2009158769 @default.
• W2021844653 cites W2012458918 @default.
• W2021844653 cites W2014140219 @default.
• W2021844653 cites W2014699813 @default.
• W2021844653 cites W2019101336 @default.
• W2021844653 cites W2020414031 @default.
• W2021844653 cites W2021327941 @default.
• W2021844653 cites W2022353753 @default.
• W2021844653 cites W2033074878 @default.
• W2021844653 cites W2033561156 @default.
• W2021844653 cites W2037241563 @default.
• W2021844653 cites W2046154378 @default.
• W2021844653 cites W2053056955 @default.
• W2021844653 cites W2070357412 @default.
• W2021844653 cites W2071663305 @default.
• W2021844653 cites W2071897904 @default.
• W2021844653 cites W2074078721 @default.
• W2021844653 cites W2078429223 @default.
• W2021844653 cites W2079249609 @default.
• W2021844653 cites W2079637753 @default.
• W2021844653 cites W2084904435 @default.
• W2021844653 cites W2102403955 @default.
• W2021844653 cites W2104622314 @default.
• W2021844653 cites W2112048790 @default.
• W2021844653 cites W2112506842 @default.
• W2021844653 cites W2113272019 @default.
• W2021844653 cites W2119763231 @default.
• W2021844653 cites W2121790486 @default.
• W2021844653 cites W2130809613 @default.
• W2021844653 cites W2138038505 @default.
• W2021844653 cites W2142436561 @default.
• W2021844653 cites W2168428762 @default.
• W2021844653 cites W4231002927 @default.
• W2021844653 cites W4248428496 @default.
• W2021844653 doi "https://doi.org/10.1089/cap.2009.0125" @default.
• W2021844653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20807067" @default.
• W2021844653 hasPublicationYear "2010" @default.
• W2021844653 type Work @default.
• W2021844653 sameAs 2021844653 @default.
• W2021844653 citedByCount "47" @default.
• W2021844653 countsByYear W20218446532012 @default.
• W2021844653 countsByYear W20218446532013 @default.
• W2021844653 countsByYear W20218446532014 @default.
• W2021844653 countsByYear W20218446532015 @default.
• W2021844653 countsByYear W20218446532016 @default.
• W2021844653 countsByYear W20218446532017 @default.
• W2021844653 countsByYear W20218446532018 @default.
• W2021844653 countsByYear W20218446532019 @default.
• W2021844653 countsByYear W20218446532020 @default.
• W2021844653 countsByYear W20218446532021 @default.
• W2021844653 countsByYear W20218446532022 @default.
• W2021844653 crossrefType "journal-article" @default.
• W2021844653 hasAuthorship W2021844653A5027835055 @default.
• W2021844653 hasAuthorship W2021844653A5035282947 @default.
• W2021844653 hasAuthorship W2021844653A5052383569 @default.
• W2021844653 hasAuthorship W2021844653A5076359094 @default.
• W2021844653 hasAuthorship W2021844653A5078144552 @default.
• W2021844653 hasConcept C118552586 @default.
• W2021844653 hasConcept C126322002 @default.
• W2021844653 hasConcept C15744967 @default.
• W2021844653 hasConcept C197934379 @default.
• W2021844653 hasConcept C2776412080 @default.
• W2021844653 hasConcept C2777026814 @default.
• W2021844653 hasConcept C2777200579 @default.
• W2021844653 hasConcept C2778375690 @default.
• W2021844653 hasConcept C2780211496 @default.
• W2021844653 hasConcept C71924100 @default.
• W2021844653 hasConceptScore W2021844653C118552586 @default.
• W2021844653 hasConceptScore W2021844653C126322002 @default.
• W2021844653 hasConceptScore W2021844653C15744967 @default.
• W2021844653 hasConceptScore W2021844653C197934379 @default.
• W2021844653 hasConceptScore W2021844653C2776412080 @default.
• W2021844653 hasConceptScore W2021844653C2777026814 @default.
• W2021844653 hasConceptScore W2021844653C2777200579 @default.
• W2021844653 hasConceptScore W2021844653C2778375690 @default.
• W2021844653 hasConceptScore W2021844653C2780211496 @default.
• W2021844653 hasConceptScore W2021844653C71924100 @default.
• W2021844653 hasIssue "4" @default.
• W2021844653 hasLocation W20218446531 @default.

• next